Abstract 2688
Background
Liver resection is a curative treatment for patients with colorectal liver metastasis (CRLM). However, about 70% patients will experience recurrence after resection. CRLM number and maximum (CRLMmax) size have been associated with recurrence after hepatic resection. Still, association between CRLM minimum (CRLMmin) size and tumor recurrence has never been evaluated. This study aimed to correlate CRLMmin on the liver specimen with recurrence free survival (RFS).
Methods
We retrospectively included all patients who underwent first laparoscopic liver resection for CRLM from January 2000 to November 2018 in a single institution. Patients with extra hepatic evolutive disease were excluded. A CRLMmin cut off was selected using the time-dependent area under the curve (td-AUC) for 1 and 2-year RFS. Cox uni and multivariate models were constructed. Multivariate analysis was completed for factors with a p value ≤ 0.10 upon univariate analysis, or previously known determinant factors. Primary end point was RFS.
Results
Overall, 227 patients were included. Median follow- up was 50 months (6-210), 151 (67%) patients presented with recurrence. The optimal CRLMmin cutoff associated with RFS was 9mm (12 and 24-months td-AUC = 0.56 and 0.52, respectively). Median RFS were respectively 11.9 months (CI 95% 7.1-18.7) in patients with CRLMmin size <9mm and 21.9 months (CI 95% 18.5-30.8) for those with CRLMmin size ≥9mm (p < 0.001). In multivariate analysis, CRLMmin size <9mm was an independent prognostic factor for RFS after adjusting on node-positive primary tumor, preoperative carcinoembryonic antigen ACE ≥5ng/ml, multiple liver metastasis and synchronous or metachronous <12months liver metastasis (HR = 1.6 (1.1-2.4); p < 0.05). Also, CRLMmin size <9mm was independently associated with hepatic RFS (HR = 1.8 (1.2-3,0); p < 0.05) but not extra-hepatic RFS.
Conclusions
The present study suggests that CRLMmin size <9mm on the liver specimen was an independent progonostic factor for worse RFS, particularly associated with poor local control over distant metastasis control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
David Fuks.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract